Relative Selectivity of Covalent Inhibitors Requires Assessment of Inactivation Kinetics and Cellular Occupancy: A Case Study of Ibrutinib and Acalabrutinib

Ibrutinib Inhibits Platelet Integrin αIIbβ3 Outside-In Signaling and Thrombus Stability But Not Adhesion to Collagen

BTK inhibitors in the treatment of hematological malignancies and inflammatory diseases: mechanisms and clinical studies, Journal of Hematology & Oncology

Frontiers Structure-Function Relationships of Covalent and Non-Covalent BTK Inhibitors

Selective Inhibition of Bruton's Tyrosine Kinase by a Designed Covalent Ligand Leads to Potent Therapeutic Efficacy in Blood Cancers Relative to Clinically Used Inhibitors

Structure of BTK kinase domain with the second-generation inhibitors acalabrutinib and tirabrutinib

Frontiers Structure-Function Relationships of Covalent and Non-Covalent BTK Inhibitors

Kinetic mechanisms of covalent inhibition - ScienceDirect

Tyrosine Kinase: Most Up-to-Date Encyclopedia, News & Reviews

PDF] Relative Selectivity of Covalent Inhibitors Requires Assessment of Inactivation Kinetics and Cellular Occupancy: A Case Study of Ibrutinib and Acalabrutinib

31st Annual Meeting and Associated Programs of the Society for Immunotherapy of Cancer (SITC 2016): part two

Toward Atomistic Modeling of Irreversible Covalent Inhibitor Binding Kinetics

Case Study - COVALfinder to Study Irreversible EGFR Drugs